More than 70 years researching and improving health
1946
Foundation of the Company
1981
Beginning of research into
low-molecular-weight heparins
1998
Launch of Bemiparin on the
Spanish market and start-up of
cooperations in Portugal
2002
Internationalization of ROVI® following
approval of Bemiparin outside Spain
2003
Increased International coverage
to 59 countries
2006
Construction of the Granada R&D&i
centre and plant
2007
Agreement with Laboratoires Servier
for the marketing of Corlentor®
2009
Strategic agreement with Merck
Sharp & Dhome (MSD)
2011
Agreement with MSD for the marketing of
Vitorin® and Absorcol®
2012
FDA certification of the
injectables plant
2013
Agreements to market products
from Novartis and Medice
2014
registration process for an
enoxaparin biosimilar with the EU
2015
Adquisition of the new injectables plant
in San Sebastián de los Reyes
Successful completion
of PRISMA-2 study
Agreement with Astellas for the
marketing of Volutsa®
2016
Agrement with Novartis for the marketing
of Neparvis® and Orexigen for the
marketing of Mysimba®
2017
Commencement of the marketing of an
enoxaparin biosimilar in Germany
Beginning of Phase III clinical trial of Doria®
(Risperidone-ISM®)
2018
Launch of an enoxaparin biosimilar in
Spain, France, United Kingdom, Italy
Austria, Estonia and Latvia
2019
Conclusion of the PRISMA-3 and BORIS
studies and end of the Clinical Research
Programme of Risperidone-ISM® - Doria® in
patients with schizophrenia and application
for marketing authorisation in Europe
Presence of enoxaparin biosimilar
in 13 countries
2020
Validation of the Doria® dossier and start of
the product evaluation process in Europe